HEM Pharma Inc. (376270.KQ) stock: key figures, P/E, revenue and dividend
Health Care · South Korea
Price
25,700.00 KRW
Market cap
184.43 bn KRW
P/E (2025)
–
P/S (2025)
14.21
Dividend yield
0.00 %
Net margin
-183.69 %
Return on equity (ROE)
-478.14 %
Return on assets (ROA)
-46.00 %
HEM Pharma Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 15.07 bn KRW | 12.98 bn KRW |
| Gross profit | 1.62 bn KRW | 631.54 m KRW |
| Operating income | -7.68 bn KRW | -15.58 bn KRW |
| EBIT | -7.35 bn KRW | -23.07 bn KRW |
| Net income | -7.65 bn KRW | -23.84 bn KRW |
| Diluted EPS – continuing operations | -1,099.83 KRW | -3,322.38 KRW |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About HEM Pharma Inc.
HEM Pharma Inc. operates as a microbiome healthcare company in South Korea and internationally. The company offers health functional food products, such as Nutrilite and my LAB microbiome solution. It also engages in the personalized analysis service and CDMO businesses. The company was founded in 2016 and is based in Pohang, South Korea.
More stocks
- T.A.C. Consumer Public Company Limited (TACC.BK)
- Hung -Gu Oil Ltd (024060.KQ)
- Norooholdings (000320.KS)
- ONYX (ONYX.AT)
- São Carlos Empreendimentos e Participações S.A (SCAR3.SA)
- MedPacto Inc (235980.KQ)
- Gladiator Metals Corp (GLAD.V)
- NOVAREX Co.Ltd (194700.KQ)
- Fwusow Industry Co Ltd (1219.TW)
- Dana Brata Luhur PT (TEBE.JK)
- Hansol Paper Co Ltd (213500.KS)
- BLUE DOLPHIN ENERGY CO (BDCO)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.